ImmuCell Corporation ICCC · Stock Open ImmuCell Corporation in new tab
ImmuCell Corporation Analysis (ICCC)
Is ImmuCell Corporation a good investment? ImmuCell Corporation (ICCC) is currently trading at 10.95 USD.
Earnings Schedule: ImmuCell Corporation is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.11.
Investor FAQ
Does ImmuCell Corporation pay a dividend?
No, it does not currently pay a dividend.
What asset class is ImmuCell Corporation?
ImmuCell Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.07.
Company Profile
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
| Split Date | Split Ratio to 1 |
|---|---|
| July 25, 1990 | 1:100 |
Community Discussion